Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)
Compose a Response to This Article
Other responses
No responses have been published for this article.
